Wacker Biosolutions to focus on biotechnology

Published: 2-Mar-2010
Manufacturing Ingredients Finance Pharmaceutical

Wacker Fine Chemicals becomes Wacker Biosolutions and concentrates on biotechnology

Wacker, the German chemical company, has changed the name of its Wacker Fine Chemicals division to Wacker Biosolutions as it gives the business a biotechnology focus.

Wacker Biosolutions will concentrate on building its business in three main areas, including pharmaceuticals, alongside its existing portfolio of fine chemicals and chemical intermediates. Its biotech products include cyclodextrins, cysteine and biologics, as well as fine chemicals and PVAc solid resins.

The Munich-based firm is currently extending process development and production capacities for the manufacture of pharmaceutical proteins at Wacker Biotech in Jena, Germany.

Wacker aims to offer tailored complete solutions to customers, taking advantage of the synergies between its chemical and biotech expertise. It sees potential in providing innovative products and technologies in the budding market for bioengineered products.

"This reorganisation lays further foundations for Wacker's future success in the growing field of biotechnology," said Gerhard Schmid, senior vice president of Wacker Biosolutions.

Over the past few years, Wacker has posted high double-digit growth with biotech products such as cyclodextrins and cysteine. The group sees future global-market potential in pharmaceutical actives, food additives and agrochemicals.

See more

You may also like

Manufacturing

Replacing discontinued OEM degasser modules

Read more
Biotech Fluidics introduces direct replacement OEM degasser modules based on upgraded vacuum technology to support continued fluidic instrument supply without costly redesigns

Trending Articles

  1. MHRA approves every-four-week dosing regimen for Chiesi's Elfabrio in stable adult Fabry disease patients The firm has received MHRA approval for an additional 2 mg/kg every-four-week dosing regimen for pegunigalsidase alfa, halving the number of annual infusions required for eligible adult Fabry disease patients from 26 to 13
  2. FDA issues first cGMP warning letter citing AI misuse in pharmaceutical manufacturing A Michigan-based lab has become the subject of the FDA's first dedicated enforcement action on artificial intelligence misuse in drug manufacturing — a landmark event with far-reaching implications for cGMP compliance across the pharmaceutical supply chain
  3. How the QA and QP Talent Market Is Changing in Pharma: Insights from Compliance Unlocked Podcast Recruiting and retaining experienced quality and regulatory professionals has become significantly more complex for pharmaceutical and biotech companies
  4. You need to be a subscriber to read this article.
    Click here to find out more.
    Rice-ing to the occasion: how plant-based excipients are gaining ground in pharmaceutical manufacturing As clean-label expectations migrate from health foods into pharmaceutical supply chains, natural ingredient supplier RIBUS says that rice-based excipients are becoming a credible alternative to synthetic standards

Upcoming event

Cleanroom Technology Conference UK

20-21 May 2026 | Conference and Exhibition | Birmingham, UK See all

You may also like

Manufacturing

Replacing discontinued OEM degasser modules

Biotech Fluidics introduces direct replacement OEM degasser modules based on upgraded vacuum technology to support continued fluidic instrument supply without costly redesigns
Manufacturing

etherna's mRNA and LNP platforms advance Dropshot Therapeutics' renal disease programme to clinical stage

etherna has announced that partner Dropshot Therapeutics has validated its platforms in preclinical renal disease research and will now progress to IND-enabling studies, with etherna providing GMP manufacturing support ahead of planned Phase I clinical trials in 2027
Manufacturing

CARBOGEN AMCIS introduces SPRINT for early-phase development

A new, phase-appropriate approach designed to accelerate early-phase progression while maintaining scientific rigour
Manufacturing

FUJIFILM Cellular Dynamics opens new iPSC manufacturing facility in US

The new site will serve as the company's headquarters and will increase Fujifilm's capacity for induced pluripotent stem cell development and manufacturing, as demand increases with new approach methods in research
You need to be a subscriber to read this article.
Click here to find out more.
Manufacturing

From bespoke to scalable: closing the manufacturing gap in advanced therapeutics

Dr Kevin Robinson (KSR) spoke to Cytiva’s Nicolas Pivet (NP), Vice President of Manufacturing and Digital Solutions, to find out how digitalisation and scalable manufacturing platforms are shaping the next phase of advanced therapeutics
Manufacturing

Piramal Pharma Solutions announces partnership with Botanix to support drug substance development

Piramal Pharma Solutions has entered into an agreement with Botanix SB Inc., a subsidiary of Botanix Pharmaceuticals Limited, to support the development and commercial supply of Sofdra. Sofdra is the first and only FDA-approved new chemical entity (NCE) for the treatment of primary axillary hyperhidrosis. Through this partnership, Piramal Pharma Solutions will leverage the strength of its North American drug substance facilities to support robust, consistent patient access to Sofdra
Manufacturing

ProtaGene and Merck partner to deliver end-to-end biologics testing

The duo will combine ProtaGene's early-stage biologics expertise with Merck's BioReliance GMP testing infrastructure, offering biopharmaceutical customers an integrated testing solution across the full drug development lifecycle
Subscribe now